APA (7th ed.) Citation

Díez, J., & Bayes‐Genis, A. (2017, October). Compelling Benefit of Soluble Suppression of Tumorigenicity‐2 in Post–Myocardial Infarction Estimation of Risk: The Time Is Right for Its Routine Use in the Clinic. Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease.

Chicago Style (17th ed.) Citation

Díez, Javier, and Antoni Bayes‐Genis. "Compelling Benefit of Soluble Suppression of Tumorigenicity‐2 in Post–Myocardial Infarction Estimation of Risk: The Time Is Right for Its Routine Use in the Clinic." Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease Oct. 2017.

MLA (9th ed.) Citation

Díez, Javier, and Antoni Bayes‐Genis. "Compelling Benefit of Soluble Suppression of Tumorigenicity‐2 in Post–Myocardial Infarction Estimation of Risk: The Time Is Right for Its Routine Use in the Clinic." Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Oct. 2017.